Melatonin in COVID-19

Phase 3

Recruiting

Conditions: COVID-19 disease.
COVID-19, virus not identified
U07.2

Registration Number: IRCT20200506047323N5

Lead Sponsor: Bandare-abbas University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 60

Inclusion Criteria

Age >20 years
Positive polymerase chain reaction (PCR) test for COVID-19 or/and lung involvement in imaging
Primary clinical symptoms
Hospitalized and moderate patients
Signing informed consent and willingness of study participant to accept randomization to any assigned treatment arm

Exclusion Criteria

Patients with underlying diseases including hypertension, diabetes, seizure, depression, chronic hepatitis, cirrhosis, and cholestatic liver diseases
Use of anticoagulant drugs like warfarin, hormonal drugs, alcohol, and any illegal drugs (during last 30 days)
History of allergy to Melatonin
Pregnancy and breastfeeding

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Body temperature. Timepoint: Before intervention and daily during the study. Method of measurement: Thermometer.;Respiratory rate. Timepoint: Before intervention and daily during the study. Method of measurement: Respiratory Count.;Oxygen saturation. Timepoint: Before intervention and daily during the study. Method of measurement: Pulse oximeter.

Secondary Outcome Measures

Name	Time	Method
ymphocytopenia. Timepoint: Before intervention and 7 days after the start of the intervention. Method of measurement: Cell count.;C-reactive protein. Timepoint: Before intervention and 7 days after the start of the intervention. Method of measurement: C-RP kit.;Incidence of serious adverse events. Timepoint: Before intervention and daily during the study. Method of measurement: Questionnaire.